[Featured Stock] EMTEC Rises 7% on FDA Approval of Co-Developed 'iMedisyn's iSyncWave' in the US

[Asia Economy Reporter Lee Seon-ae] EMTEK's stock price is showing a rise of over 7% after the market opened on the 1st. This is interpreted as a result of buying interest following iMediSyn's announcement that their EEG measurement device iSyncWave received FDA approval on the 10th.

At 9:25 AM on the same day, EMTEK was trading at 29,000 KRW, up 7.21% compared to the previous trading day.

The FDA-approved iSyncWave is a dry EEG measurement device that does not require conductive gel. It is adjustable in a variable form to fit various head shapes according to the international EEG measurement standard 10/20 system, making it easy to wear and measure. Additionally, it is linked to a big data-based cloud automatic analysis system, enabling rapid analysis of quantitative EEG data.

EMTEK is a co-developer of iMediSyn's 'iSyncWave.' EMTEK has designated the healthcare business as its next third major business following its current core businesses of mobile components and electronic cigarettes, and it is expected to start generating sales related to the new business from this year.

The new healthcare business is classified into medical devices and beauty devices. In the case of medical devices, the dry EEG measurement device iSyncWave, supplied to iMediSyn, obtained certification from the Ministry of Food and Drug Safety in November 2021, and full-scale sales are expected to begin in the first half of this year. Additional development of medical devices incorporating precision IT technology is also underway. For beauty devices, a product lineup supplying to Mediheal Cube Age-R and Amorepacific MakeON has been established, and mass production and sales realization are anticipated at the newly established Dongtan healthcare business site this year.